natgillin/translations-raw huggingface dataset:
Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface.
Klopidogrel njihovo agregacijo zavira tako, da snovi, imenovani ADP, prepreči, da bi se vezala na posebne receptorje na njihovi površini.
The European Medicines Agency concluded that, in accordance with EU requirements, Clopidogrel TAD has been shown to have comparable quality and to be bioequivalent to Plavix.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima to zdravilo primerljivo raven kakovosti kot referenčno zdravilo Plavix ter da mu je biološko enakovredno.
It is not intended to provide practical advice on how to use Clopidogrel TAD.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Clopidogrel TAD is available as tablets containing 75 mg clopidogrel.
Zdravilo Klopidogrel TAD je na voljo v obliki tablet, ki vsebujejo 75 mg klopidogrela.
For practical information about using Clopidogrel TAD, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Klopidogrel TAD naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The Agency recommended that Clopidogrel TAD be approved for use in the EU.
Priporočila je, da se zdravilo odobri za uporabo v EU.
Why is Clopidogrel TAD approved?
Zakaj je bilo zdravilo Klopidogrel TAD odobreno?
• recently had an ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
• so nedavno utrpeli ishemično kap (kap zaradi neoskrbe določenega dela možganov s krvjo).
Because Clopidogrel TAD is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Ker je zdravilo Klopidogrel TAD generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Plavix.
Clopidogrel TAD is a ‘generic medicine'.
Klopidogrel TAD je „generično zdravilo“.
• atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
• trpijo za atrijsko fibrilacijo (nerednim hitrim krčenjem zgornjih srčnih preddvorov), pri katerih se mora zdravilo dajati skupaj z aspirinom.
Clopidogrel TAD can be started between seven days and six months after the stroke;
Zdravilo Klopidogrel TAD se lahko začne jemati od sedem dni po napadu do šest mesecev po njem;
Therefore, the Agency's view was that, as for Plavix, the benefit outweighs the identified risk.
Zato je menila, da njegove koristi enako kot pri zdravilu Plavix odtehtajo znana tveganja.
Other information about Clopidogrel TAD
Druge informacije o zdravilu Klopidogrel TAD
When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together).
Strjevanje krvi je posledica agregacije (zlepljanja) posebnih celic v krvi, imenovanih trombociti.
• a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots).
• imajo akutni koronarni sindrom, pri katerem se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov).
Some of these patients may have had a stent (a short tube) placed in an artery to prevent it from closing up;
Nekaterim bolnikom je bil morda v arterijo vstavljen stent (kratka cevka), da prepreči njeno zamašitev;
The active substance in Clopidogrel TAD, clopidogrel, is an inhibitor of platelet aggregation.
Zdravilna učinkovina zdravila Klopidogrel TAD, klopidogrel, je zaviralec agregacije trombocitov.
How has Clopidogrel TAD been studied?
Kako je bilo zdravilo Klopidogrel TAD raziskano?
How is Clopidogrel TAD used?
Kako se zdravilo Klopidogrel TAD uporablja?
Clopidogrel TAD contains the active substance clopidogrel.
Zdravilo Klopidogrel TAD vsebuje zdravilno učinkovino klopidogrel.
How does Clopidogrel TAD work?
Kako zdravilo Klopidogrel TAD deluje?
Clopidogrel TAD can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Klopidogrel TAD je le na recept.
This summary was last updated in 11-2017.
Povzetek je bil nazadnje posodobljen 11-2017.
The first dose should be followed by 3 more doses after 2, 4, and 9 weeks and then one dose every 4 months thereafter.
Prvemu odmerku morajo slediti še trije odmerki po 2, 4 in 9 tednih, nato pa en odmerek na vsake štiri mesece.
This replaces the missing protein, thereby relieving the symptoms of the disease.
S tem nadomesti manjkajočo beljakovino in olajša simptome bolezni.
The European Commission granted a marketing authorisation valid throughout the European Union for Spinraza on 30 May 2017.
Evropska komisija je dovoljenje za promet z zdravilom Spinraza, veljavno po vsej Evropski uniji, izdala 30. maja 2017.
In babies some side effects could not be assessed, as they could not communicate them.
Pri dojenčkih določenih neželenih učinkov ni bilo mogoče oceniti zaradi njihove nezmožnosti sporočanja.
In its assessment, the European Medicines Agency recognised the serious nature of the disease and the urgent need for effective treatments.
Evropska agencija za zdravila je v svoji oceni prepoznala resnost bolezni in nujno potrebo po učinkovitem zdravljenju.
What measures are being taken to ensure the safe and effective use of Spinraza?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Spinraza?
Although the medicine was not tested in patients with the most severe and the mildest forms of SMA, it is expected to provide similar benefits to these patients.
Čeprav zdravilo pri bolnikih z najhujšo in najbolj blago obliko SMA ni bilo preskušeno, se pričakujejo podobne koristi zdravljenja tudi pri teh bolnikih.
The disease is linked to a defect on chromosome 5q and symptoms usually start shortly after birth.
Bolezen je povezana z okvaro na kromosomu 5q, simptomi pa se običajno pojavijo kmalu po rojstvu.
This is a summary of the European public assessment report (EPAR) for Spinraza.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Spinraza.
The most common side effects with Spinraza (which may affect more than 1 in 10 people) are headache, back pain and vomiting.
Najpogostejši neželeni učinki zdravila Spinraza (ki lahko prizadenejo več kot 1 osebo od 10) so glavobol, bolečine v hrbtu in bruhanje.
The recommended dose is 12 mg (one vial), given as soon as possible after the patient has been diagnosed with SMA.
Priporočeni odmerek je 12 mg (ena viala), ki ga je treba dati čim prej po postavitvi diagnoze SMA.
It is given by intrathecal injection (into the lower back, directly into the spine) by a doctor or nurse experienced in carrying out this procedure.
Z intratekalno injekcijo (v spodnji del hrbta, neposredno v hrbtenico) ga daje zdravnik ali medicinska sestra, ki ima izkušnje z izvajanjem tega posega.
The company that markets Spinraza will complete ongoing studies of the long-term safety and effectiveness of the medicine in patients who are showing symptoms of SMA and patients not yet showing symptoms.
Družba, ki trži zdravilo Spinraza, bo dokončala potekajoče študije dolgoročne varnosti in učinkovitosti zdravila pri bolnikih, ki kažejo simptome SMA, in bolnikih, ki simptomov še ne kažejo.
In addition, most babies treated with Spinraza survived for longer and needed breathing support later than those given placebo.
Poleg tega so dojenčki, ki so bili zdravljeni z zdravilom Spinraza, večinoma preživeli dlje kot tisti, ki so prejemali placebo, in so podporo dihanju potrebovali pozneje.
The summary of the opinion of the Committee for Orphan Medicinal Products for Spinraza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Povzetek mnenja Odbora za zdravila sirote o zdravilu Spinraza je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
After one year of treatment, 51% of babies receiving Spinraza (37 out of 73) showed progress in developing head control, rolling, sitting, crawling, standing and walking, whereas no similar progress was seen in any of the babies who received placebo.
Po enem letu zdravljenja, se je pri 51 % (37 od 73) dojenčkov, ki so prejemali zdravilo Spinraza pokazalo napredovanje pri razvoju obvladovanja glave, kotaljenja, sedenja, plazenja, stoječega položaja in hoje, pri dojenčkih, ki so prejemali placebo, pa podobno napredovanje ni bilo ugotovljeno v nobenem primeru.
The SMN protein is made from two genes, SMN1 and SMN2.
Beljakovino SMN sestavljata dva gena, SMN1 in SMN2.
The Agency therefore decided that Spinraza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Agencija je zato zaključila, da so koristi zdravila Spinraza večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
What is Spinraza and what is it used for?
Kaj je zdravilo Spinraza in za kaj se uporablja?
Because the number of patients with SMA is low, the disease is considered ‘rare', and Spinraza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 2 April 2012.
Ker je bolnikov s SMA malo, velja ta bolezen za redko, zato je bilo zdravilo Spinraza 2. aprila 2012 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Other information about Spinraza
Druge informacije o zdravilu Spinraza
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Spinraza have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Spinraza upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
What are the risks associated with Spinraza?
Kakšna tveganja so povezana z zdravilom Spinraza?
Another study assessed Spinraza's effectiveness in children whose SMA was less severe and diagnosed at a later stage (average age of 3 years).
V drugi študiji so ocenili učinkovitost zdravila Spinraza pri otrocih, pri katerih je SMA manj huda in je bila diagnoza postavljena pozneje (pri povprečni starosti treh let).
What benefits of Spinraza have been shown in studies?
Kakšne koristi je zdravilo Spinraza izkazalo v študijah?
One main study, involving 121 babies (of an average age of 7 months) with SMA, showed that Spinraza is effective in improving movement when compared with placebo (sham injection).
Ena glavna študija, v katero je bilo vključenih 121 dojenčkov (povprečne starosti 7 mesecev) s SMA, je pokazala, da zdravilo Spinraza v primerjavi s placebom (injekcijo brez zdravilne učinkovine) učinkovito izboljša gibanje.
For more information about treatment with Spinraza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Spinraza preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Side effects were considered manageable, with most side effects related to the way the medicine is given.
Neželeni učinki veljajo za obvladljive in so večinoma povezani z načinom dajanja zdravila.
The medicine is available as a solution for injection in 12 mg vials.
Na voljo je v obliki raztopine za injiciranje v vialah z 12 mg učinkovine.
It is not intended to provide practical advice on how to use Spinraza.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
After 15 months of treatment, 57% of children receiving Spinraza showed improvement in movement compared with 26% of children on placebo.
Po 15 mesecih zdravljenja, je bilo pri 57 % otrok, ki so prejemali zdravilo Spinraza, ugotovljeno izboljšanje gibanja, medtem ko je bilo med otroci, ki so prejemali placebo, takšnih otrok 26 %.
The full EPAR for Spinraza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Spinraza je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For the full list of all side effects and restrictions with Spinraza, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Spinraza glejte navodilo za uporabo.
Spinraza is a medicine used to treat 5q spinal muscular atrophy (SMA), a genetic disease that causes weakness and wasting of the muscles including the lung muscles.
Spinraza je zdravilo, ki se uporablja za zdravljenje 5q spinalne mišične atrofije (SMA), genetske bolezni, ki povzroča šibkost in atrofijo mišic, tudi dihalnih.
Spinraza has been shown to lead to clinically meaningful improvements in young children with varying degrees of disease severity.
Zdravilo Spinraza je pri majhnih otrocih z različno stopnjo resnosti bolezni pokazalo klinično pomembna izboljšanja.
Why is Spinraza approved?
Zakaj je bilo zdravilo Spinraza odobreno?
For practical information about using Spinraza, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Spinraza naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
These side effects are thought to be caused by the injections into the spine used to give the medicine.
Te neželene učinke naj bi povzročale injekcije v hrbtenico, s katerimi se zdravilo daje.
Spinraza can only be obtained with a prescription and treatment should be started by a doctor with experience in the treatment of SMA.
Predpisovanje in izdaja zdravila Spinraza je le na recept, zdravljenje pa mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem SMA.
Patients with SMA lack a protein called ‘survival motor neuron' (SMN) protein, which is essential for motor neurons (nerve cells from the spinal cord that control muscle movements) to survive and function normally.
Bolnikom s SMA primanjkuje beljakovine, imenovane „beljakovina preživetja motoričnega nevrona“ (SMN), ki je nujna za preživetje in normalno delovanje motoričnih nevronov (živčnih celic v hrbtenjači, ki nadzorujejo gibe mišic).
Patients with SMA lack the SMN1 gene but have the SMN2 gene, which mostly produces a short SMN protein that does not work as well as a full-length protein.
Bolnikom s SMA primanjkuje gena SMN1, gen SMN2 pa imajo, zato se tvori predvsem kratka beljakovina SMN, ki ne deluje enako dobro kot beljakovina s celotno dolžino.
Spinraza is a synthetic anti-sense oligonucleotide (a type of genetic material) that enables the SMN2 gene to produce full length protein, which is able to work normally.
Zdravilo Spinraza je sintetični protismiselni oligonukleotid (vrsta genetskega materiala), ki genu SMN2 omogoči tvorbo beljakovine s celotno dolžino in normalnim delovanjem.
Spinraza contains the active substance nusinersen.
Zdravilo Spinraza vsebuje zdravilno učinkovino nusinersen.
How is Spinraza used?
Kako se zdravilo Spinraza uporablja?
How does Spinraza work?
Kako zdravilo Spinraza deluje?
Treatment should be continued for as long as the patient benefits from it. For further information, see the package leaflet.
Zdravljenje z zdravilom Spinraza se nadaljuje tako dolgo, dokler je za bolnika koristno.
Other opportunistic infections
Druge oportunistične okužbe
You and your doctor should pay special attention to signs of infection while you are being treated with Hyrimoz.
Vi sami in vaš zdravnik morata biti posebej pozorna na znake okužbe, medtem ko ste zdravljeni z zdravilom Hyrimoz.
If you have any questions, please talk to a doctor, pharmacist or nurse who is familiar with Hyrimoz.
Če imate kakršna koli vprašanja, se pogovorite z zdravnikom, farmacevtom ali medicinsko sestro, ki so seznanjeni z zdravilom Hyrimoz.
Side effects may occur up to 4 months or more after the last Hyrimoz injection.
Neželeni učinki se lahko pojavijo do 4 mesece ali več po zadnji injekciji zdravila Hyrimoz.
Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).
Aktivna tuberkuloza ali druge hude okužbe, npr. sepsa, in oportunistične okužbe (glejte poglavje 4.4).
Keep this Patient Reminder Card with you during your treatment and for 4 months after your (or your child's) last injection of Hyrimoz.
To opozorilno kartico za bolnika imejte pri sebi med zdravljenjem in še štiri mesece po svoji zadnji injekciji (ali zadnji injekciji vašega otroka) zdravila Hyrimoz.
If you accidentally inject Hyrimoz more frequently than you should, call your doctor or pharmacist and explain that you have taken more than required.
Če pomotoma injicirate zdravilo Hyrimoz pogosteje, kot bi smeli, se morate posvetovati z zdravnikom ali s farmacevtom in mu pojasniti, da ste uporabili večji odmerek, kot ga potrebujete.
• If you are over 65 years you may be more susceptible to infections while taking Hyrimoz.
• Če ste starejši od 65 let, ste morda dovzetnejši za okužbe, če jemljete zdravilo Hyrimoz.
In all situations described below, the benefit / risk balance of therapy should be very carefully considered.
V vseh spodaj opisanih okoliščinah je treba korist in tveganje zdravljenja z zdravilom Hyrimoz zelo natančno pretehtati.
• On rare occasions, treatment with Hyrimoz could result in lupus-like syndrome.
• V redkih primerih zdravljenje z zdravilom Hyrimoz povzroči lupusu podoben sindrom.
The decision to stop using Hyrimoz should be discussed with your doctor.
O odločitvi, da bi prenehali uporabljati zdravilo Hyrimoz, se morate posvetovati s svojim zdravnikom.
Treatment with Hyrimoz can be initiated in combination with corticosteroids and/or with other non-biologic immunomodulatory agents.
Zdravljenje z zdravilom Hyrimoz se lahko začne v kombinaciji s kortikosteroidi in/ali z drugimi nebiološkimi imunomodulatorji.
For patients who test positive for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.
Pri bolnikih, ki so pozitivni na okužbo s hepatitisom B, se priporoča posvetovanje z zdravnikom specialistom za zdravljenje okužb s hepatitisom B.
Hyrimoz in combination with methotrexate, is indicated for:
Zdravilo Hyrimoz je v kombinaciji z metotreksatom indicirano za:
• Certain vaccines contain living but weakened forms of disease-causing bacteria or viruses and should not be given during treatment with Hyrimoz in case they cause infections.
• Določena cepiva lahko vsebujejo žive, vendar oslabljene oblike bakterij ali virusov, ki povzročajo bolezen, in teh cepiv se med zdravljenjem z zdravilom Hyrimoz ne sme uporabljati, da ne bi povzročila okužb.
If you receive Hyrimoz while you are pregnant, your baby may be at higher risk for getting an infection for up to about five months after the last dose you received during pregnancy.
Če prejemate zdravilo Hyrimoz med nosečnostjo, obstaja večje tveganje, da bo vaš otrok dobil okužbo do približno pet mesecev po zadnjem odmerku, ki ste ga prejeli med nosečnostjo.
If you forget to give yourself an injection, you should inject the next dose of Hyrimoz as soon as you remember.
Če si pozabite dati injekcijo, si morate naslednji odmerek zdravila Hyrimoz injicirati, čim se spomnite.
• As cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will check you for signs and symptoms of tuberculosis before starting Hyrimoz.
• Ker so bili pri bolnikih, zdravljenih z adalimumabom, opisani primeri tuberkuloze, vas bo zdravnik pred začetkom zdravljenja z zdravilom Hyrimoz preiskal glede znakov in simptomov tuberkuloze.
Contents of the pack and other information What Hyrimoz contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Hyrimoz
Hyrimoz can also be given alone.
Zdravilo Hyrimoz se lahko daje tudi samo.
• If you have allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling or rash, do not inject more Hyrimoz and contact your doctor immediately, since in rare cases, these reactions can be life-threatening.
• Če imate alergijske reakcije s simptomi, kot so tiščanje v prsih, piskajoče dihanje, omotica, otekanje ali izpuščaj, zdravila Hyrimoz ne injicirajte več in se takoj posvetujte s svojim zdravnikom, saj so v redkih primerih te reakcije lahko življenje ogrožajoče.
Patients on Hyrimoz may receive concurrent vaccinations, except for live vaccines.
Bolniki, ki prejemajo zdravilo Hyrimoz, lahko sočasno dobijo cepiva, razen živih cepiv.
Your doctor may recommend temporarily stopping Hyrimoz.
Vaš zdravnik bo morda priporočil začasno prekinitev uporabe zdravila Hyrimoz.
By attaching to TNFα, Hyrimoz blocks its action and reduces the inflammation in these diseases.
Z vezavo na TNFα zdravilo Hyrimoz zavre njegovo delovanje in zmanjša vnetni proces pri teh boleznih.
• If you receive Hyrimoz during your pregnancy, your baby may have a higher risk for getting an infection.
• Če prejmete zdravilo Hyrimoz med nosečnostjo, obstaja večje tveganje, da bo vaš dojenček dobil okužbo.
Before initiation of therapy with Hyrimoz, all patients must be evaluated for both active and inactive (“latent”) tuberculosis infection.
Pred začetkom zdravljenja z zdravilom Hyrimoz je vse bolnike treba pregledati glede aktivne in neaktivne (latentne) tuberkulozne okužbe.
The impact of long-term treatment with adalimumab on the development of autoimmune diseases is unknown.
Vpliv dolgoročnega zdravljenja z adalimumabom na nastanek avtoimunskih bolezni ni znan.
If active tuberculosis is diagnosed, Hyrimoz therapy must not be initiated (see section 4.3).
Če se odkrije aktivna tuberkuloza, se zdravljenja z zdravilom Hyrimoz ne sme začeti (glejte poglavje 4.3).
Treatment with Hyrimoz should not be initiated in patients with active infections including chronic or localised infections until infections are controlled.
Zdravljenja z zdravilom Hyrimoz se ne sme začeti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi, dokler te niso obvladane.
The potential risk with the combination of azathioprine or 6mercaptopurine and Hyrimoz should be carefully considered.
Potrebno je upoštevati potencialno tveganje pri sočasni uporabi azatioprina ali 6-merkaptopurina in zdravila Hyrimoz.
Keep Hyrimoz and all medicines out of the reach of children.
Zdravilo Hyrimoz in vsa zdravila shranjujte nedosegljivo otrokom.
• When needed (for example when you are travelling), Hyrimoz may be stored at room temperature (up to 25°C) for a maximum period of 14 days - be sure to protect it from light.
• Če je potrebno (na primer kadar potujete), lahko zdravilo Hyrimoz hranite pri sobni temperaturi (do 25 °C) največ 14 dni - zagotovite, da bo zaščiteno pred svetlobo.
You should not take Hyrimoz with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection.
Zdravila Hyrimoz ne smete jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Other medicines and Hyrimoz
Druga zdravila in zdravilo Hyrimoz
Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Hyrimoz.
Kortikosteroide, ki se jih daje sočasno, se lahko postopoma ukinja v skladu s klinično prakso, z začetkom dva tedna po začetku zdravljenja z zdravilom Hyrimoz.
What you need to know before you use Hyrimoz Do not use Hyrimoz
Kaj morate vedeti, preden boste uporabili zdravilo Hyrimoz Ne uporabljajte zdravila Hyrimoz
Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Hyrimoz in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.
O uporabi protituberkuloznega profilaktičnega zdravljenja morate pred uvedbo zdravila Hyrimoz razmisliti tudi pri bolnikih s hudimi ali pomembnimi faktorji tveganja za tuberkulozo kljub negativnemu testu za tuberkulozo in pri bolnikih z anamnezo latentne ali aktivne tuberkuloze, pri katerih ni mogoče potrditi ustreznega zdravljenja.
What Hyrimoz is and what it is used for
Kaj je zdravilo Hyrimoz in za kaj ga uporabljamo